Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 24 peer-reviewed journal articles Updated
Gynecologic Oncology

Treatment Strategies: Surgery and Beyond

At a Glance

Standard ovarian cancer treatments often do not work for rare subtypes. Expert surgery is the essential first step, followed by treatments tailored to the specific tumor biology. This may include fertility-sparing surgery, targeted therapies like MEK inhibitors, or specific chemotherapy regimens.

When you have a rare ovarian cancer, the biggest risk is being treated entirely with the “standard” playbook designed for common high-grade serous ovarian cancer (HGSOC). While general principles apply, treatment guidelines from major organizations like the NCCN (National Comprehensive Cancer Network) and ESMO (European Society for Medical Oncology) emphasize that “one size does not fit all” [1][2].

Step 1: Expert Surgical Removal

For almost all rare ovarian cancers, surgery is the absolute first step and the cornerstone of treatment [3][4]. Before any targeted pills or systemic therapies are considered, a gynecologic oncologist must perform surgery to remove the tumor and determine its stage.

  • Maximal Debulking: For types like Clear Cell or LGSOC, the goal is often to remove all visible disease, as these tumors do not shrink as easily with pre-surgical chemotherapy as high-grade tumors do [3][5].
  • Fertility-Sparing Surgery (FSS): Many rare cancers, particularly Germ Cell and Sex Cord-Stromal tumors, affect younger people [6]. If the cancer is caught early (Stage I), removing only the affected ovary while leaving the uterus and the other ovary is often the standard, safe approach [7][8].

The Chemoresistance Challenge

A major reason why standard ovarian cancer treatment doesn’t always work for rare types is chemoresistance. Many rare epithelial tumors do not respond robustly to standard platinum-and-taxane chemotherapy [2][9].

  • Low-Grade Serous (LGSOC): This cancer grows slowly and is less impacted by traditional chemo [10]. Guidelines now suggest targeted therapies like MEK inhibitors (e.g., trametinib) or endocrine (hormonal) therapy (e.g., letrozole) as vital strategies, especially for recurrent disease [11][12][1].
  • Clear Cell Carcinoma: Often resistant to standard platinum chemo, research for Clear Cell is shifting toward immune-related treatments and targeted clinical trials [13][14].
  • Mucinous Carcinoma: Up to 25% of these tumors are HER2-positive [15]. For these patients, drugs that target HER2 (like trastuzumab) may be considered over standard regimens [16][17].

When Chemotherapy is Highly Effective

While chemoresistance is a challenge for some rare tumors, it is exactly the opposite for others.

  • Germ Cell Tumors: These non-epithelial tumors are exceptionally sensitive to specialized chemotherapy. For patients with advanced disease, a highly specific regimen (most commonly BEP: bleomycin, etoposide, and cisplatin) is used. It is this aggressive, targeted chemotherapy that makes germ cell tumors so highly curable [18][19][20].

A Specialized Strategy for Each Type

If your doctor is pushing for immediate, standard chemotherapy without discussing the following tailored options, it may be time for a second opinion:

Subtype The Modern Strategy Key Drugs/Approaches
LGSOC Surgery, then target the “growth switch” (MAPK pathway) or block hormones. MEK inhibitors (Trametinib), Letrozole [11][21].
Mucinous Surgery; test for HER2; personalized systemic therapy. Trastuzumab, Enhertu (if HER2+) [15][22].
Germ Cell Fertility-sparing surgery; utilize specific chemo for advanced stages. BEP chemotherapy [7][23].
Sex Cord Surgical removal first; hormonal therapy generally reserved for recurrence. Expert surgery, endocrine therapy [8][24].

The goal is to match the treatment to the biology of your specific tumor. Applying the “standard” playbook to these rare diseases without accounting for their unique behaviors is increasingly considered outdated practice. To ensure you have access to these targeted treatments, you need the right doctors, which is covered in Expertise Matters: Building Your Care Team.

Common questions in this guide

Is standard chemotherapy always used for rare ovarian cancers?
No, standard chemotherapy is often less effective for rare ovarian cancers like low-grade serous (LGSOC) and clear cell carcinomas due to chemoresistance. Treatment should be tailored to your specific tumor type, often utilizing targeted therapies or specialized regimens instead.
Am I a candidate for fertility-sparing surgery?
Fertility-sparing surgery involves removing only the affected ovary while leaving the uterus and healthy ovary intact. This is often a safe, standard approach for younger patients with early-stage germ cell or sex cord-stromal tumors.
How is low-grade serous ovarian cancer (LGSOC) treated?
Treatment for LGSOC typically begins with expert surgery to remove as much of the tumor as possible. Because LGSOC is slow-growing and often resistant to standard chemotherapy, targeted therapies like MEK inhibitors or hormone-blocking medications are often recommended instead.
Are there targeted treatments for mucinous ovarian cancer?
Up to a quarter of mucinous ovarian tumors are HER2-positive. If tumor testing confirms this, you may be a candidate for targeted therapies like trastuzumab or Enhertu rather than standard chemotherapy regimens.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my rare subtype, is an aggressive upfront surgery to remove all visible disease the recommended first step?
  2. 2.Since LGSOC and Clear Cell are often chemoresistant, why are we choosing standard carboplatin-taxane right now instead of a targeted therapy or clinical trial?
  3. 3.Is my mucinous tumor HER2-positive? If so, are we considering targeted therapies like trastuzumab or Enhertu?
  4. 4.Am I a candidate for fertility-sparing surgery? Specifically, can we preserve my uterus and one ovary while still ensuring the cancer is properly treated?
  5. 5.If I have a Germ Cell tumor, what is the exact chemotherapy regimen planned, and how does it impact my long-term health?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (24)
  1. 1

    NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.

    Armstrong DK, Alvarez RD, Backes FJ, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2022; (20(9)):972-980.

    PMID: 36075393
  2. 2

    New therapeutic opportunities for women with low-grade serous ovarian cancer.

    Moujaber T, Balleine RL, Gao B, et al.

    Endocrine-related cancer 2021; (29(1)):R1-R16.

    PMID: 34636747
  3. 3

    Comparison of surgical and oncologic outcomes in patients with clear cell ovarian carcinoma associated with and without endometriosis.

    Charatsingha R, Hanamornroongruang S, Benjapibal M, et al.

    Archives of gynecology and obstetrics 2021; (304(6)):1569-1576 doi:10.1007/s00404-021-06096-6.

    PMID: 34023979
  4. 4

    Incidence of lymph node metastasis in early-stage low-grade serous ovarian cancer: a systematic review.

    Viveros-Carreño D, Rodriguez J, Pareja R

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2022; (32(10)):1283-1288 doi:10.1136/ijgc-2022-003618.

    PMID: 35831031
  5. 5

    Primary versus interval cytoreductive surgery in patients with rare epithelial or non-epithelial ovarian cancer.

    Fumagalli D, Jayraj A, Olearo E, et al.

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2025; (35(3)):101664 doi:10.1016/j.ijgc.2025.101664.

    PMID: 40022844
  6. 6

    Differences in Characteristics and Outcomes Between Large-Cell Neuroendocrine Carcinoma of the Ovary and High-Grade Serous Ovarian Cancer: A Retrospective Observational Cohort Study.

    Pang L, Guo Z

    Frontiers in oncology 2022; (12()):891699 doi:10.3389/fonc.2022.891699.

    PMID: 35600342
  7. 7

    Fertility-Sparing Surgery for Ovarian Cancer.

    Canlorbe G, Chabbert-Buffet N, Uzan C

    Journal of clinical medicine 2021; (10(18)) doi:10.3390/jcm10184235.

    PMID: 34575345
  8. 8

    Adult ovarian granulosa cell tumors: analysis of outcomes and risk factors for recurrence.

    Plett H, Ricciardi E, Vacaru V, et al.

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2023; (33(5)):734-740 doi:10.1136/ijgc-2022-003854.

    PMID: 36759002
  9. 9

    The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance.

    Cobb LP, Sun CC, Iyer R, et al.

    Gynecologic oncology 2020; (158(3)):653-658 doi:10.1016/j.ygyno.2020.06.498.

    PMID: 32709538
  10. 10

    Therapeutic advances and molecular insights in low-grade serous ovarian carcinoma.

    Kabirian R, Gaillard T, Bello-Roufai D, et al.

    Bulletin du cancer 2026; (113(4)):533-540 doi:10.1016/j.bulcan.2025.11.005.

    PMID: 41402140
  11. 11

    Low-grade Serous Tumors: Are We Making Progress?

    Pauly N, Ehmann S, Ricciardi E, et al.

    Current oncology reports 2020; (22(1)):8 doi:10.1007/s11912-020-0872-5.

    PMID: 31989304
  12. 12

    Cost-effectiveness of maintenance hormonal therapy in patients with advanced low grade serous ovarian cancer.

    Nica A, Lee JYJ, Hong NL, May T

    Gynecologic oncology 2021; (160(1)):206-213 doi:10.1016/j.ygyno.2020.09.051.

    PMID: 33032821
  13. 13

    Treatment of ovarian clear cell carcinoma with immune checkpoint blockade: a case series.

    Sia TY, Manning-Geist B, Gordhandas S, et al.

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2022; (32(8)):1017-1024 doi:10.1136/ijgc-2022-003430.

    PMID: 35545291
  14. 14

    Disparity in the era of personalized medicine for epithelial ovarian cancer.

    Devlin MJ, Miller RE

    Therapeutic advances in medical oncology 2023; (15()):17588359221148024 doi:10.1177/17588359221148024.

    PMID: 36643655
  15. 15

    HER2/ ERBB2 Immunohistochemical Expression and Copy Number Status in Ovarian Mucinous Tumors.

    Smithgall MC, Yemelyanova A, Mathew S, et al.

    International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2024; (43(2)):134-139 doi:10.1097/PGP.0000000000000966.

    PMID: 37406458
  16. 16

    HER2 mutation profiling in mucinous ovarian carcinoma: Inferences for Enhertu (trastuzumab deruxtecan) as a potential therapeutic approach.

    Shen HP, Lee MY, Chao WR, et al.

    Taiwanese journal of obstetrics & gynecology 2025; (64(5)):802-808 doi:10.1016/j.tjog.2025.04.013.

    PMID: 40935457
  17. 17

    Durable remission in a patient with ERBB2-amplified recurrent mucinous ovarian carcinoma treated with Trastuzumab-Carboplatin-Paclitaxel.

    Neil AJ, Muto MG, Kolin DL, Konstantinopoulos PA

    Gynecologic oncology reports 2023; (48()):101237 doi:10.1016/j.gore.2023.101237.

    PMID: 37449085
  18. 18

    Balancing efficacy with long-term side-effects: can we safely de-escalate therapy for germ cell tumors?

    Shamash J, Ng K

    Expert review of anticancer therapy 2023; (23(2)):127-134 doi:10.1080/14737140.2023.2162042.

    PMID: 36648077
  19. 19

    HNF1β is a sensitive and specific novel marker for yolk sac tumor: a tissue microarray analysis of 601 testicular germ cell tumors.

    Gallo A, Fankhauser C, Hermanns T, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2020; (33(11)):2354-2360 doi:10.1038/s41379-020-0597-x.

    PMID: 32561848
  20. 20

    Salvage Therapy for Patients With Germ Cell Tumor.

    Rashdan S, Einhorn LH

    Journal of oncology practice 2016; (12(5)):437-43 doi:10.1200/JOP.2016.011411.

    PMID: 27170693
  21. 21

    Endocrine therapy in epithelial ovarian cancer.

    Langdon SP, Gourley C, Gabra H, Stanley B

    Expert review of anticancer therapy 2017; (17(2)):109-117 doi:10.1080/14737140.2017.1272414.

    PMID: 27967255
  22. 22

    Mucinous ovarian cancer: A therapeutic review.

    Xu W, Rush J, Rickett K, Coward JI

    Critical reviews in oncology/hematology 2016; (102()):26-36.

    PMID: 27083591
  23. 23

    Reproductive Outcomes and Fertility Preservation Strategies in Women with Malignant Ovarian Germ Cell Tumors after Fertility Sparing Surgery.

    Vasta FM, Dellino M, Bergamini A, et al.

    Biomedicines 2020; (8(12)) doi:10.3390/biomedicines8120554.

    PMID: 33265938
  24. 24

    Could fertility-sparing surgery be considered for stage I ovarian sex cord-stromal tumors? A comparison of the Fine-Gray model with Cox model.

    Sun D, Zhi ZF, Fan JT

    Frontiers in oncology 2022; (12()):964181 doi:10.3389/fonc.2022.964181.

    PMID: 36158691

This page discusses general treatment strategies for rare ovarian cancers for educational purposes only. Always consult a specialized gynecologic oncologist to determine the most appropriate surgical and medical treatment plan for your specific tumor subtype.

Get notified when new evidence is published on Rare ovarian cancer.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.